Table of Contents Author Guidelines Submit a Manuscript
Anemia
Volume 2015, Article ID 763576, 10 pages
http://dx.doi.org/10.1155/2015/763576
Research Article

Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations

1Luitpold Pharmaceuticals, Inc., Norristown, PA 19403, USA
2St. John’s University, Jamaica, NY 11439, USA
3Department of Pathology and Medicine (Hematology), Stanford, CA 94305, USA

Received 6 May 2015; Revised 18 June 2015; Accepted 23 June 2015

Academic Editor: Bruno Annibale

Copyright © 2015 Todd A. Koch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. T. Goodnough, “The new age of iron: evaluation and management of iron-restricted erythropoiesis,” Seminars in Hematology, vol. 46, no. 4, pp. 325–327, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Annibale, G. Capurso, A. Chistolini et al., “Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms,” The American Journal of Medicine, vol. 111, no. 6, pp. 439–445, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. P. L. Acher, T. Al-Mishlab, M. Rahman, and T. Bates, “Iron-deficiency anaemia and delay in the diagnosis of colorectal cancer,” Colorectal Disease, vol. 5, no. 2, pp. 145–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Raje, H. Mukhtar, A. Oshowo, and C. Ingham Clark, “What proportion of patients referred to secondary care with iron deficiency anemia have colon cancer?” Diseases of the Colon and Rectum, vol. 50, no. 8, pp. 1211–1214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Auerbach, J. A. Pappadakis, H. Bahrain, S. A. Auerbach, H. Ballard, and N. V. Dahl, “Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia,” American Journal of Hematology, vol. 86, no. 10, pp. 860–862, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. T. Goodnough, E. Nemeth, and T. Ganz, “Detection, evaluation, and management of iron-restricted erythropoiesis,” Blood, vol. 116, no. 23, pp. 4754–4761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Auerbach, H. Ballard, J. R. Trout et al., “Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1301–1307, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Auerbach, “Ferumoxytol as a new, safer, easier-to-administer intravenous iron: yes or no?” The American Journal of Kidney Diseases, vol. 52, no. 5, pp. 826–829, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Bonnar, A. Goldberg, and J. A. Smith, “Do pregnant women take their iron?” The Lancet, vol. 1, no. 7592, pp. 457–458, 1969. View at Google Scholar · View at Scopus
  10. G. Weiss and L. T. Goodnough, “Anemia of chronic disease,” The New England Journal of Medicine, vol. 352, no. 10, pp. 1011–1059, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. N. C. Andrews, “Anemia of inflammation: the cytokine-hepcidin link,” Journal of Clinical Investigation, vol. 113, no. 9, pp. 1251–1253, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. L. T. Goodnough and A. Shander, “Current status of pharmacologic therapies in patient blood management,” Anesthesia & Analgesia, vol. 116, no. 1, pp. 15–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. H. Henry, N. V. Dahl, M. Auerbach, S. Tchekmedyian, and L. R. Laufmane, “Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy,” Oncologist, vol. 12, no. 2, pp. 231–242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Hedenus, G. Birgegard, P. Nasman et al., “Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study,” Leukemia, vol. 21, no. 4, pp. 627–632, 2007. View at Publisher · View at Google Scholar
  15. L. Bastit, A. Vandebroek, S. Altintas et al., “Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1611–1618, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Gafter-Gvili, D. P. Steensma, and M. Auerbach, “Should the ASCO/ASH guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated?” Journal of the National Comprehensive Cancer Network, vol. 12, no. 5, pp. 657–664, 2014. View at Google Scholar · View at Scopus
  17. J. A. Gilreath, D. D. Stenehjem, and G. M. Rodgers, “Diagnosis and treatment of cancer-related anemia,” American Journal of Hematology, vol. 89, no. 2, pp. 203–212, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Auerbach, A. S. Liang, and J. Glaspy, “Intravenous iron in chemotherapy and cancer-related anemia,” Community Oncology, vol. 9, no. 9, pp. 289–295, 2012. View at Publisher · View at Google Scholar
  19. J. D. Rizzo, M. Brouwers, P. Hurley, J. Seidenfeld, M. R. Somerfield, and S. Temin, “American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer,” Journal of Oncology Practice, vol. 6, no. 6, pp. 317–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. D. S. Silverberg, A. Iaina, G. Peer et al., “Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis,” American Journal of Kidney Diseases, vol. 27, no. 2, pp. 234–238, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. R. S. Hillman and P. A. Henderson, “Control of marrow production by the level of iron supply,” Journal of Clinical Investigation, vol. 48, no. 3, pp. 454–460, 1969. View at Publisher · View at Google Scholar · View at Scopus
  22. R. L. Jurado, “Iron, infections, and anemia of inflammation,” Clinical Infectious Diseases, vol. 25, no. 4, pp. 888–895, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Bishu and R. Agarwal, “Acute injury with intravenous iron and concerns regarding long-term safety,” Clinical Journal of the American Society of Nephrology, supplement 1, pp. S19–S23, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. L. T. Goodnough, J. H. Levy, and M. F. Murphy, “Concepts of blood transfusion in adults,” The Lancet, vol. 381, no. 9880, pp. 1845–1854, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. D. R. Spahn and L. T. Goodnough, “Alternatives to blood transfusion,” The Lancet, vol. 381, no. 9880, pp. 1855–1865, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. L. T. Goodnough, “Blood management: transfusion medicine comes of age,” The Lancet, vol. 381, no. 9880, pp. 1791–1792, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Shander, R. K. Spence, and M. Auerbach, “Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?: report from the Society for the Advancement of Blood Management 2008 Annual Meeting,” Transfusion, vol. 50, no. 3, pp. 719–732, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Auerbach, L. T. Goodnough, D. Picard, and A. Maniatis, “The role of intravenous iron in anemia management and transfusion avoidance,” Transfusion, vol. 48, no. 5, pp. 988–1000, 2008. View at Google Scholar · View at Scopus
  29. G. M. Chertow, P. D. Mason, O. Vaage-Nilsen, and J. Ahlmén, “Update on adverse drug events associated with parenteral iron,” Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 378–382, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. Dexferrum [package insert], American Regent, Shirley, NY, USA, 2008.
  31. INFeD, Package Insert, Watson Pharma, Morristown, NJ, USA, 2009.
  32. A. M. Ganzoni, “Intravenous iron-dextran: therapeutic and experimental possibilities,” Schweizerische Medizinische Wochenschrift, vol. 100, no. 7, pp. 301–303, 1970. View at Google Scholar · View at Scopus
  33. American Regent, Venofer [Package Insert], American Regent, Shirley, NY, USA, 2012.
  34. Ferrlecit, Package Insert, Sanofi-Aventis US, Bridgewater, NJ, USA, 2011.
  35. Feraheme [package insert], AMAG Pharmaceuticals, Lexington, Mass, USA, 2015.
  36. American Regent, Injectafer [Package Insert], American Regent, Shirley, NY, USA, 2013.
  37. S. Kulnigg, S. Stoinov, V. Simanenkov et al., “A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial,” The American Journal of Gastroenterology, vol. 103, no. 5, pp. 1182–1192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. D. B. van Wyck, M. G. Martens, M. H. Seid, J. B. Baker, and A. Mangione, “Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial,” Obstetrics and Gynecology, vol. 110, no. 2, pp. 267–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. D. B. van Wyck, A. Mangione, J. Morrison, P. E. Hadley, J. A. Jehle, and L. T. Goodnough, “Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial,” Transfusion, vol. 49, no. 12, pp. 2719–2728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. H. Seid, R. J. Derman, J. B. Baker, W. Banach, C. Goldberg, and R. Rogers, “Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial,” American Journal of Obstetrics & Gynecology, vol. 199, no. 4, pp. 435.e1–435.e7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. C. F. Barish, T. Koch, A. Butcher, D. Morris, and D. B. Bregman, “Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials,” Anemia, vol. 2012, Article ID 172104, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Hussain, J. Bhoyroo, A. Butcher, T. A. Koch, A. He, and D. B. Bregman, “Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia,” Anemia, vol. 2013, Article ID 169107, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. J. E. Onken, D. B. Bregman, R. A. Harrington et al., “A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia,” Transfusion, vol. 54, no. 2, pp. 306–315, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. J. E. Onken, D. B. Bregman, R. A. Harrington et al., “Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial,” Nephrology Dialysis Transplantation, vol. 29, no. 4, pp. 833–842, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. National Kidney Foundation. KDOQI, “Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease,” American Journal of Kidney Diseases, vol. 47, supplement 3, pp. S1–S145, 2006. View at Google Scholar
  46. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group, “KDIGO clinical practice guideline for anemia in chronic kidney disease,” Kidney International Supplements, vol. 2, no. 4, pp. S279–S335, 2012. View at Google Scholar
  47. National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology. Cancer- and Chemotherapy-Induced Anemia. Version 2, NCCN, 2015.
  48. M. Aapro, A. Österborg, P. Gascón, H. Ludwig, and Y. Beguin, “Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of I.V. iron,” Annals of Oncology, vol. 23, no. 8, pp. 1954–1962, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Gasche, A. Berstad, R. Befrits et al., “Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases,” Inflammatory Bowel Diseases, vol. 13, no. 12, pp. 1545–1553, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Gozzard, “When is high-dose intravenous iron repletion needed? Assessing new treatment options,” Drug Design, Development and Therapy, no. 5, pp. 51–60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Geisser and V. Rumyantsev, “Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder,” Arzneimittelforschung, vol. 60, no. 6, pp. 373–385, 2010. View at Google Scholar · View at Scopus
  52. R. R. Crichton, B. Danielson, and P. Geisser, Iron Therapy with Special Emphasis on Intravenous Administration, UNI-MED, Bremen, Germany, 4th edition, 2008.
  53. B. G. Danielson, “Structure, chemistry, and pharmacokinetics of intravenous iron agents,” Journal of the American Society of Nephrology, vol. 15, no. 2, pp. S93–S98, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Geisser, M. Baer, and E. Schaub, “Structure/histotoxicity relationship of parenteral iron preparations,” Drug Research, vol. 42, no. 12, pp. 1439–1452, 1992. View at Google Scholar · View at Scopus
  55. S. Beshara, H. Lundqvist, J. Sundin et al., “Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography,” British Journal of Haematology, vol. 104, no. 2, pp. 296–302, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Geisser and S. Burckhardt, “The pharmacokinetics and pharmacodynamics of iron preparations,” Pharmaceutics, vol. 3, no. 1, pp. 12–33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Malone, C. Barish, A. He, and D. Bregman, “Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients,” Obesity Surgery, vol. 23, no. 9, pp. 1413–1420, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. K. A. Lyseng-Williamson and G. M. Keating, “Ferric carboxymaltose: a review of its use in iron-deficiency anaemia,” Drugs, vol. 69, no. 6, pp. 739–756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Evstatiev, P. Marteau, T. Iqbal et al., “FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease,” Gastroenterology, vol. 141, no. 3, pp. 846.e2–853.e2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. X. Calvet, M. À. Ruíz, A. Dosal et al., “Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency,” PLoS ONE, vol. 7, no. 9, Article ID e45604, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. F. Gomollón and J. P. Gisbert, “Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide,” Drugs, vol. 73, no. 16, pp. 1761–1770, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. A. A. Khalafallah and A. E. Dennis, “Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy,” Journal of Pregnancy, vol. 2012, Article ID 630519, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus